<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00086879</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-26034-16031</org_study_id>
    <secondary_id>EORTC-26034-16031</secondary_id>
    <nct_id>NCT00086879</nct_id>
  </id_info>
  <brief_title>Erlotinib Compared With Temozolomide or Carmustine in Treating Patients With Recurrent Glioblastoma Multiforme</brief_title>
  <official_title>Randomized Phase II of TARCEVA™ (Erlotinib) Versus Temozolomide Or BCNU in Patients With Recurrent Glioblastoma Multiforme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for&#xD;
      their growth. Drugs used in chemotherapy, such as temozolomide and carmustine, work in&#xD;
      different ways to stop tumor cells from dividing so they stop growing or die. It is not yet&#xD;
      known whether erlotinib is more effective than temozolomide or carmustine in treating&#xD;
      recurrent glioblastoma multiforme.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying erlotinib to see how well it works&#xD;
      compared to temozolomide or carmustine in treating patients with recurrent glioblastoma&#xD;
      multiforme.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare the therapeutic activity of erlotinib vs temozolomide or carmustine in patients&#xD;
           with recurrent glioblastoma multiforme.&#xD;
&#xD;
        -  Compare 6-month progression-free survival in patients treated with these drugs.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare the safety of these drugs in these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified&#xD;
      according to participating center. Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive oral erlotinib* once daily on day 1-28. Courses repeat every 28&#xD;
           days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      NOTE: *Patients treated with enzyme inducing anti-epileptic drugs (EIAEDs) receive a higher&#xD;
      dose of erlotinib than patients not receiving any anti-epileptic drugs or EIAEDs.&#xD;
&#xD;
        -  Arm II: Patients who have not received prior temozolomide are assigned to receive&#xD;
           temozolomide. Patients who have received prior temozolomide are assigned to receive&#xD;
           carmustine. Patients receive 1 of the following treatment regimens:&#xD;
&#xD;
             -  Patients receive oral temozolomide* once daily on days 1-5. Courses repeat every 28&#xD;
                days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
             -  Patients receive carmustine IV once daily on days 1-3. Treatment repeats every 56&#xD;
                days for up to 5 courses in the absence of disease progression or unacceptable&#xD;
                toxicity.&#xD;
&#xD;
      NOTE: *Chemotherapy-naïve patients receive a higher dose of temozolomide than patients who&#xD;
      have received prior adjuvant chemotherapy.&#xD;
&#xD;
      Patients are followed every 8 weeks until disease progression and then every 3 months&#xD;
      thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 100-110 patients (50-55 per treatment arm) will be accrued for&#xD;
      this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival at 6 months</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response (complete [CR] or partial response [PR]) measured by McDonald's criteria at least 4 weeks after first documented response and every 8 weeks until disease progression or until start of another treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe toxic events assessed by CTCAE v3.0 at the end of each course</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival at 1 year</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival at 6 months and 1 year</measure>
  </secondary_outcome>
  <enrollment type="Actual">110</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carmustine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temozolomide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed glioblastoma multiforme&#xD;
&#xD;
               -  Some oligodendroglial elements allowed provided they make up &lt; 25% of the tumor&#xD;
&#xD;
          -  Recurrent disease documented by MRI after prior radiotherapy&#xD;
&#xD;
          -  At least 1 bidimensionally measurable target lesion ≥ 2 cm by MRI&#xD;
&#xD;
          -  Undergone prior surgery for recurrent primary brain tumor more than 3 months before&#xD;
             study entry&#xD;
&#xD;
               -  Must have a clearly limited target lesion ≥ 2 cm OR evidence of progressive and&#xD;
                  measurable target lesion OR a second measurable target lesion outside the&#xD;
                  surgical area&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Over 18&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm ^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  AST and ALT &lt; 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin &lt; 1.5 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine &lt; 1.5 times ULN&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  Clinically normal cardiac function&#xD;
&#xD;
          -  No ischemic heart disease within the past 12 months&#xD;
&#xD;
          -  No New York Heart Association grade III or IV cardiac insufficiency&#xD;
&#xD;
          -  No unstable angina&#xD;
&#xD;
          -  No arryhthmia&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  DLCO &gt; 70% of predicted (for patients randomized to receive erlotinib [arm I] or&#xD;
             carmustine [arm II])&#xD;
&#xD;
          -  No history of pulmonary disease that would affect pulmonary function including any of&#xD;
             the following:&#xD;
&#xD;
               -  Chronic bronchopneumopathy&#xD;
&#xD;
               -  Pleural effusion&#xD;
&#xD;
               -  Interstitial pnuemonia&#xD;
&#xD;
               -  Pulmonary lymphangitis&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after study&#xD;
             participation&#xD;
&#xD;
          -  No other malignancy except cone biopsied carcinoma of the cervix or adequately treated&#xD;
             basal cell or squamous cell skin cancer&#xD;
&#xD;
          -  No psychological, familial, sociological, or geographical factors that would preclude&#xD;
             study compliance&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No prior HER-targeted agents&#xD;
&#xD;
          -  No concurrent growth factors for neutrophil count elevation&#xD;
&#xD;
          -  No concurrent epoetin alfa&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Prior adjuvant temozolomide allowed&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)&#xD;
&#xD;
          -  No more than 1 prior adjuvant chemotherapy regimen&#xD;
&#xD;
          -  No prior chemotherapy for recurrent disease&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Must be on a stable or decreasing dose of corticosteroids for at least 2 weeks before&#xD;
             study entry&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 3 months since prior radiotherapy to the brain&#xD;
&#xD;
          -  No prior high-dose radiotherapy (&gt; 65 Gy), stereotactic radiosurgery, or internal&#xD;
             radiotherapy unless disease recurrence confirmed&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No prior participation in experimental therapies&#xD;
&#xD;
          -  No concurrent CYP3A4 inhibitors (e.g., ketoconazole, erythromycin, troleandomycin,&#xD;
             cimetidine, or grapefruit juice)&#xD;
&#xD;
          -  No concurrent warfarin or other coumarin derivatives&#xD;
&#xD;
               -  Concurrent low-molecular weight heparin allowed&#xD;
&#xD;
          -  No other concurrent investigational drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin J. van Den Bent, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Daniel Den Hoed Cancer Center at Erasmus Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>U.Z. Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Lutte Contre le Cancer Georges-Francois Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional Rene Gauducheau</name>
      <address>
        <city>Nantes-Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Pitie-Salpetriere</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>F-94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Padova</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Haaglanden</name>
      <address>
        <city>'s-Gravenhage</city>
        <zip>2501 CK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Rotterdam at Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3000 CA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Infirmary</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G11 6NT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>van den Bent MJ, Brandes AA, Rampling R, Kouwenhoven MC, Kros JM, Carpentier AF, Clement PM, Frenay M, Campone M, Baurain JF, Armand JP, Taphoorn MJ, Tosoni A, Kletzl H, Klughammer B, Lacombe D, Gorlia T. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol. 2009 Mar 10;27(8):1268-74. doi: 10.1200/JCO.2008.17.5984. Epub 2009 Feb 9.</citation>
    <PMID>19204207</PMID>
  </results_reference>
  <results_reference>
    <citation>van den Bent MJ, Brandes A, Rampling R, et al.: Randomized phase II trial of erlotinib (E) versus temozolomide (TMZ) or BCNU in recurrent glioblastoma multiforme (GBM): EORTC 26034. [Abstract] J Clin Oncol 25 (Suppl 18): A-2005, 2007.</citation>
  </results_reference>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>July 8, 2004</study_first_submitted>
  <study_first_submitted_qc>July 9, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2004</study_first_posted>
  <last_update_submitted>July 26, 2017</last_update_submitted>
  <last_update_submitted_qc>July 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult glioblastoma</keyword>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Carmustine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

